Education
About Us
Working with TipRanks
Follow Us
McKesson Corporation (MCK)
NYSE:MCK
MCK Stock Chart & Stats
$840.46
$1.72(0.29%)
At close: 4:00 PM EST
$840.46
$1.72(0.29%)
Day’s Range― - ―
52-Week Range$570.51 - $895.58
Previous CloseN/A
Volume137.88K
Average Volume (3M)578.52K
Market Cap
$103.74B
Enterprise Value$110.22B
Total Cash (Recent Filing)$4.11B
Total Debt (Recent Filing)$9.79B
Price to Earnings (P/E)26.2
Beta0.28
Next Earnings
Feb 04, 2026EPS Estimate
9.16Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)9.86
Shares Outstanding123,426,650
10 Day Avg. Volume588,180
30 Day Avg. Volume578,518
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)-41.34
Price to Sales (P/S)0.24
P/FCF Ratio16.41
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue0.28
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda18.74
Forecast
1Y Price Target
$950.45Price Target Upside13.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)38.94
Revenue Forecast (FY)$408.07B
Bulls Say, Bears Say
Bulls Say
Acquisitions And Organic GrowthRecent PRISM and FCS acquisitions materially boosted Oncology and Multispecialty performance while underlying organic growth in the segment remained ahead of long-term targets.
Earnings GuidanceManagement raised full-year adjusted earnings guidance and consolidated operating income targets, indicating increased confidence in the company's profitability trajectory.
Specialty Distribution StrengthRobust specialty distribution and higher prescription volumes in pharmacy and prescription technology services support revenue and margin expansion in North America Pharma.
Bears Say
High ExpectationsElevated consensus expectations raise the bar for future results and may limit upside in the share price despite operational improvements.
Medical-surgical Segment MissMedical-surgical operating income missed analyst consensus, underscoring softness in that product segment and potential pressure on overall profitability.
McKesson News
MCK FAQ
What was McKesson Corporation’s price range in the past 12 months?
McKesson Corporation lowest stock price was $570.51 and its highest was $895.58 in the past 12 months.
What is McKesson Corporation’s market cap?
McKesson Corporation’s market cap is $103.74B.
When is McKesson Corporation’s upcoming earnings report date?
McKesson Corporation’s upcoming earnings report date is Feb 04, 2026 which is in 15 days.
How were McKesson Corporation’s earnings last quarter?
McKesson Corporation released its earnings results on Nov 05, 2025. The company reported $9.86 earnings per share for the quarter, beating the consensus estimate of $9.03 by $0.83.
Is McKesson Corporation overvalued?
According to Wall Street analysts McKesson Corporation’s price is currently Undervalued.
Does McKesson Corporation pay dividends?
McKesson Corporation pays a Quarterly dividend of $0.82 which represents an annual dividend yield of 0.37%. See more information on McKesson Corporation dividends here
What is McKesson Corporation’s EPS estimate?
McKesson Corporation’s EPS estimate is 9.16.
How many shares outstanding does McKesson Corporation have?
McKesson Corporation has 123,426,650 shares outstanding.
What happened to McKesson Corporation’s price movement after its last earnings report?
McKesson Corporation reported an EPS of $9.86 in its last earnings report, beating expectations of $9.03. Following the earnings report the stock price went up 1.7%.
Which hedge fund is a major shareholder of McKesson Corporation?
Currently, no hedge funds are holding shares in MCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$950.45 (13.09% Upside)
$950.45 (13.09% Upside)
Blogger Sentiment
Bullish
MCK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 9.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.20%
Trailing 12-Months
Company Description
McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
MCK Company Deck
MCK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
McKesson reported strong financial performance with significant growth in revenue and earnings, driven by robust performance in oncology and multispecialty segments and prescription technology solutions. The company raised its earnings guidance, reflecting confidence in continued growth. However, challenges in the Medical-Surgical Solutions segment present some concerns. Overall, the strengths significantly outweigh the challenges.View all MCK earnings summariesMCK Revenue Breakdown
91.27% U.S. Pharmaceutical
1.45% Prescription Technology Solutions
3.17% Medical-Surgical Solutions
4.10% International
<0.01% Corporate
MCK Stock 12 Month Forecast
Average Price Target
$950.45
▲(13.09% Upside)
Technical Analysis
Ownership Overview
0.03% Insiders
23.73% Mutual Funds
0.36% Other Institutional Investors
54.00% Public Companies and Individual Investors